If they are interested. Even in the four categories they're keeping it's a broad pipeline. The problem is it's second tier stuff that has a narrow focus for effect.. An IL-5 inhibitor for pulmonary diseases, a GM-CSF that failed in Covid and rheumatoid arthritis phase 2 - but they're still going for phase 3, an IBAT inhibitor, ADC targeting antigen for cancer etc. The problem is they may not want to recognize their pipeline is mediocre.

They're obviously cost cutting so I don't see them doing a buyout offer. They might partner on trials for a slice of the pie but they'll want another slice of that pie on every indication going forward.

https://www.gsk.com/en-gb/innovation/pipeline/